Proton-Pump Inhibitor Exposure Aggravates Clostridium difficile-Associated Colitis: Evidence From a Mouse Model

Area of Science:

• Gastroenterology
• Microbiology
• Immunology

Background:

• Clostridium difficile infection (CDI) is a major cause of hospital-acquired infectious diarrhea.
• Predisposing factors for CDI include age, hospitalization duration, and acid-suppressive drugs.
• The role of proton pump inhibitors (PPIs) in CDI risk remains debated.

Purpose of the Study:

• To investigate the impact of PPIs on the severity of C. difficile-associated colitis.
• To elucidate the inflammatory and barrier dysfunction associated with PPI use during CDI.

Main Methods:

• Established a mouse model of antibiotic-associated C. difficile colitis.
• Utilized NF-κB reporter mice for in vivo inflammatory pattern analysis.
• Assessed intestinal barrier permeability using serum lipopolysaccharide and dextran-FITC levels.

Main Results:

• Mice with CDI exposed to PPIs showed increased stool and weight loss.
• PPI exposure led to greater neutrophilic infiltration, epithelial damage, and inflammatory cytokine expression.
• Increased gut barrier permeability and more severe inflammatory responses were observed in PPI-exposed mice.

Conclusions:

• PPI exposure exacerbates intestinal inflammation in a mouse model of CDI.
• This study supports PPIs as a risk factor contributing to increased CDI severity.